Ms. Hougen is our executive vice president of Finance and chief financial officer. As a member of our executive leadership team, Ms. Hougen contributes to the execution of our strategy, including ensuring we are well positioned to be a global, multi-product sustainably profitable company. Ionis’ finance, accounting, tax, treasury, information technology, procurement and investor relations functions report to her. Ms. Hougen joined Ionis in May 2000 as vice president, finance, and became chief accounting officer in January 2007 and chief financial officer in January 2013.
Ms. Hougen has an extensive finance and business background having held positions of increasing responsibility in numerous public companies, primarily in the life sciences industry, over her more than 25-year career. Prior to joining Ionis, Ms. Hougen was chief financial officer for Molecular Biosystems, Inc., a public biotechnology company.
In recognition of her important contributions to the financial success of Ionis, in 2018 Ms. Hougen was named a CFO of the Year by the San Diego Business Journal. Ms. Hougen received her M.B.A. from the University of San Diego and her B.A. from Franklin and Marshall College.
What is Elizabeth L. Hougen's net worth?
The estimated net worth of Elizabeth L. Hougen is at least $4.52 million as of March 17th, 2026. Ms. Hougen owns 82,660 shares of Ionis Pharmaceuticals stock worth more than $4,519,436 as of August 4th. This net worth approximation does not reflect any other assets that Ms. Hougen may own. Learn More about Elizabeth L. Hougen's net worth.
How do I contact Elizabeth L. Hougen?
Has Elizabeth L. Hougen been buying or selling shares of Ionis Pharmaceuticals?
Elizabeth L. Hougen has not been actively trading shares of Ionis Pharmaceuticals over the course of the past ninety days. Most recently, Elizabeth L. Hougen sold 10,172 shares of the business's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $73.21, for a transaction totalling $744,692.12. Following the completion of the sale, the executive vice president now directly owns 82,660 shares of the company's stock, valued at $6,051,538.60. Learn More on Elizabeth L. Hougen's trading history.
Who are Ionis Pharmaceuticals' active insiders?
Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Shannon Devers (Executive Vice President, Chief Human Resources Officer), Allene Diaz (Director), Richard Geary (EVP), Michael Hayden (Director), Elizabeth Hougen (CFO), Kyle Jenne (Executive Vice President, Chief Global Product Strategy Officer), Joseph Klein, III (Director), Holly Kordasiewicz (Executive Vice President, Chief Development Officer), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), Eric Swayze (EVP), and Joseph Wender (Director). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?
During the last year, Ionis Pharmaceuticals insiders bought shares 2 times. They purchased a total of 20,000 shares worth more than $1,058,700.00. During the last year, insiders at the sold shares 100 times. They sold a total of 2,280,228 shares worth more than $164,273,069.83. The most recent insider tranaction occured on July, 31st when Director Michael R Hayden bought 5,000 shares worth more than $258,000.00. Insiders at Ionis Pharmaceuticals own 1.8% of the company.
Learn More about insider trades at Ionis Pharmaceuticals. Information on this page was last updated on 7/31/2026.
